Our investigation revealed that FABP3 plasma levels were elevated across all groups, including patients with MCI, AD, PD, and DLB, compared to the CN group, which is consistent with the serum levels reported in previous studies [2,20,21,23]. This evidence concerns the gene FABP3 and Alzheimer disease.